Literature DB >> 21712287

Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction.

Tialda Hoekstra1, Ivonne Lesman-Leegte, Dirk J van Veldhuisen, Robbert Sanderman, Tiny Jaarsma.   

Abstract

AIMS: To compare quality of life (QoL) in heart failure (HF) patients with preserved ejection fraction (HF-PEF) and HF patients with reduced ejection fraction (HF-REF) in a well-defined HF population. METHODS AND
RESULTS: Patients with HF-PEF [left ventricular ejection fraction (LVEF) ≥40%] were matched by age and gender to patients with HF-REF (LVEF <40%). In the current study, we only included HF patients with a B-type natriuretic peptide level (BNP) >100 pg/mL. Quality of life was assessed by Cantril's Ladder of Life, RAND-36, and the Minnesota Living with Heart Failure questionnaire, and impairment of QoL was adjusted for by BNP as a marker for severity of HF. We examined a total of 290 HF patients, of whom 145 had HF-PEF (41% female; age 72 ± 10; LVEF 51 ± 8%) and 145 had HF-REF (41% female; age 73 ± 10, LVEF 26 ± 7%). All HF patients reported markedly low scores of QoL, both on the general and disease-specific QoL questionnaires. Quality of life between patients with HF-PEF and HF-REF did not differ significantly. When adjusting the QoL scores for BNP, an association between QoL and LVEF was not found, i.e. patients with HF-PEF and HF-REF with similar BNP levels had the same impairment in QoL.
CONCLUSION: Quality of life is similarly impaired in patients with HF-PEF as in HF-REF. These findings further support the need for more pharmacological and non-pharmacological studies in patients with HF-PEF. TRIAL REGISTRATION NUMBER: NCT 98675639.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712287     DOI: 10.1093/eurjhf/hfr072

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  30 in total

Review 1.  Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations.

Authors:  Julio A Chirinos
Journal:  J Cardiovasc Transl Res       Date:  2017-04-11       Impact factor: 4.132

Review 2.  Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations.

Authors:  Julio A Chirinos
Journal:  J Cardiovasc Transl Res       Date:  2017-02-16       Impact factor: 4.132

Review 3.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 4.  The emerging epidemic of heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Jonathan D Rich; Sanjiv J Shah
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy.

Authors:  Buntaro Fujita; Marcus Franz; Bjoern Goebel; Michael Fritzenwanger; Hans R Figulla; Friedhelm Kuethe; Markus Ferrari; Christian Jung
Journal:  Clin Res Cardiol       Date:  2012-03-28       Impact factor: 5.460

Review 6.  Use of speckle tracking to assess heart failure with preserved ejection fraction.

Authors:  John B Hiebert; James Vacek; Zubair Shah; Faith Rahman; Janet D Pierce
Journal:  J Cardiol       Date:  2019-07-12       Impact factor: 3.159

Review 7.  Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Sanjiv J Shah
Journal:  Curr Cardiol Rep       Date:  2014-12       Impact factor: 2.931

8.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

Review 9.  The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.

Authors:  Julio A Chirinos; Payman Zamani
Journal:  Curr Heart Fail Rep       Date:  2016-02

10.  Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.

Authors:  Susan M Joseph; Eric Novak; Suzanne V Arnold; Philip G Jones; Himad Khattak; Anne E Platts; Victor G Dávila-Román; Douglas L Mann; John A Spertus
Journal:  Circ Heart Fail       Date:  2013-10-15       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.